CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in
precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of
3,817,000 shares of its common stock at a price to the public of $131.00 per share. In addition, Sarepta has granted the
underwriters a 30-day option to purchase up to an additional 572,550 shares of its common stock on the same terms and conditions as
the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the
underwriter discounts and commissions and other offering expenses, to be approximately $500,000,000, excluding any exercise of the
underwriters’ option to purchase additional shares. The offering is expected to close on or about November 13, 2018, subject to
customary closing conditions.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as
joint book-running managers of the proposed offering. Cowen and Company LLC is acting as sole lead manager. In addition,
William Blair & Company, L.L.C., Robert W. Baird & Co. Incorporated, Nomura Securities International, Inc., Cantor Fitzgerald & Co.
and H.C. Wainwright & Co. LLC are acting as co-managers.
Sarepta intends to use the net proceeds from the offering principally for the continuation and initiation of
further clinical trials, commercialization, manufacturing, business development activities including the potential licensing or
acquisition of complementary products and technologies and other general corporate purposes.
The shares are being offered by Sarepta pursuant to an effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement relating to and describing
the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from the offices
of Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866)
471-2526, or by email at prospectus-ny@ny.email.gs.com; or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus
Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037. This press release does not constitute an
offer to sell or a solicitation of an offer to buy any securities of Sarepta, nor shall there be any sale of securities in any
state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains statements that are forward-looking within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statements about the completion and
timing of the proposed public offering of Sarepta’s common stock and the intended use of net proceeds. These forward-looking
statements involve risks and uncertainties, many of which are beyond Sarepta’s control, including risk and uncertainties related to
market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no
assurance that Sarepta will be able to complete the public offering on the anticipated terms, or at all. Applicable risks also
include those that are included in the “Risk Factors” section of Sarepta’s Annual Report on Form 10-K for the year ended December
31, 2017, and any subsequent SEC filings, including the final prospectus supplement related to the proposed offering to be filed
with the SEC. Any forward-looking statement in this press release represents Sarepta’s views only as of the date of this press
release and should not be relied upon as representing its views as of any subsequent date. Sarepta does not undertake any
obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as
required by applicable law.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Jerica Pitts, 312-858-3469
jpitts@w2ogroup.com
